Europe approves Keytruda for first-line head and neck squamous cell carcinoma, as a monotherapy or combo
pharmafile | November 20, 2019 | News story | Research and Development, Sales and Marketing | Cancer, keytruda, pharma
MSD’s top-selling immunotherapy Keytruda (pembrolizumab) has secured another approval from the European Commission, this time in the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in patients whose tumours express PD-L1.
Phase 3 data supporting the application demonstrated that Keytruda significantly improved overall survival compared with standard treatment (cetuximab with carboplatin or cisplatin plus 5-FU), either as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy.
“This disease is especially debilitating since it can be highly visible and affect a patient’s appearance and their daily functions, such as eating and speaking,” said Professor Kevin Harrington, Professor of Biological Cancer Therapies at The Institute of Cancer Research, Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust and investigator for the Keytruda trial. “Considering the great need for new treatment options, we are encouraged by today’s Keytruda approval in Europe, which will allow certain patients to be treated with immunotherapy earlier in the course of their treatment.”
Dr Jonathan Cheng, Vice President, Clinical Research at MSD, also commented: “Keytruda is now the first anti-PD-1 treatment option in the first-line setting for metastatic or unresectable recurrent head and neck cancer, a disease that has been treated the same way in the EU for more than a decade. The European Commission approval underscores our commitment to transforming the way cancer is treated around the world.”
Matt Fellows
Related Content
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
